<DOC>
	<DOC>NCT00616447</DOC>
	<brief_summary>This study will compare the change detected by a standardized rating scale (Hamilton Anxiety Rating Scale) scores in the active treatment group as compared to sham (placebo) group after 6 weeks of rTMS treatments. It is hoped that 6 weeks of rTMS treatment will lead to improvement of core symptoms in patients with GAD.</brief_summary>
	<brief_title>rTMS Treatment in Patients With General Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>signed patient informed consent; primary GAD diagnosis; HARS &gt;=15; male/female 1865 years; without GAD pharmacotherapy at least last 2 weeks or if they are taking GAD medication it must be stable for at least 6 weeks prior to the start of the study and not be changed during the 6 weeks of the study treatment phase. Individual or group supportive psychotherapy may continue during the study but will not be allowed to start new psychotherapy during the 6 weeks of the study treatment phase. current serious Axis I schizophrenia, bipolar I, MDD; other primary Axis I in the opinion of investigator; HDRS &gt;=18; metallic implant in cranium except mouth; severe/unstable medical conditions; ect within last 3 months; history epilepsy; neurological disorder leading to increased intracranial pressure; severe cardiac disorder/intracardiac lines/pacemakers; current suicide risk.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>